Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agere Expands cGMP Spray Dry Manufacturing Capabilities

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
Solubility CRO/CMO now supports clients from formulation design through phase IIb manufacturing.

Agere Pharmaceuticals, Inc. has announced that it has added the capability to support clients entering Phase IIb clinical trials with cGMP manufacturing.

The new capacity extends the services to pharmaceutical companies that currently partner with Agere for formulation development to improve oral bioavailability of their BCS II and IV compounds.

By expanding cGMP manufacturing services, Agere now offers its clients one-stop-shopping from concept development through manufacturing for advanced clinical trials.

Outsourcing research and development to CROs is a widespread and growing practice for pharmaceutical and biotechnology companies.

The trend toward relying on a single service provider for research into clinical trial manufacturing eliminates costs, delays and risks inherent in switching vendors.

“We’ve extended our cGMP spray drying capabilities in response to our clients’ requests to continue with Agere as they enter Phase IIb clinical trials,” commented Marshall Crew, Agere’s President and CEO. “This is a natural progression for us, as expanding services delivers efficiencies to our clients.”

Pharmaceutical companies facing solubility challenges with active pharmaceutical ingredients (APIs) depend on Agere’s expertise and scientific approach to enhance the bioavailability of their drugs.

Agere services span formulation design and development into clinical trial drug product manufacturing. All services are offered “à la carte,” allowing companies the flexibility to engage with Agere at any stage in their process.

Agere provides all services on a fee-for-service basis, in which Agere assumes no intellectual property (IP) ownership over work done on behalf of the company’s clients.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!